Reestablishing Sleep and Circadian Alignment in MICU Patients Via a Mechanistic RCT of an Sleep Chronobundle (ReAlign-ICU)
Primary Purpose
Critical Illness, Sleep Deprivation, Circadian Rhythm Sleep Disorder, Unspecified
Status
Not yet recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Chronobundle - light
chronobundle - feeding
chronobundle - mobility
chronobundle - sleep
Sponsored by
About this trial
This is an interventional treatment trial for Critical Illness focused on measuring critical illness, sleep deficiency, circadian misalignment
Eligibility Criteria
Inclusion:
- MICU patients admitted within 24 hours as of 09:00 on day of enrollment (study day 1).
- Intubated and not having passed a spontaneous breathing trial or expected to be extubated in the next 24 hours as of enrollment.
- Age greater than or equal to 18 years old.
Exclusion:
- Not expected to make >250 mL urine per 24 hours.
- Imminently dying or with a hospice status.
- At significant risk for pre-existing circadian abnormalities including: (1) severe chronic brain injury (injury greater than 30 days ago resulting in the inability to live independently); (2) acute brain injury of any severity (injury less than 30 days ago including acute intracranial bleed, traumatic brain injury, central nervous system infection, tumor); (3) documented circadian disorder (<1% population) or blind/disease of the optic nerve; (4) current or recent (last 1 year) shiftwork; and (5) homelessness, incarceration, or institutionalization.
- At elevated risk of aspiration due to structural or functional abnormality of the gastrointestinal tract.
- Diabetic patients based on chart diagnosis including description of diabetes in the past medical history, the presence of a diabetes medication on the confirmed home medication list or a Hemoglobin A1C greater than or equal to 6.5%.
- Admitted due to complications of a suicide attempt.
- Admitted due to an acute drug overdose or active alcohol withdrawal.
For the Oral glucose tolerance testing sub-study, we will EXCLUDE PATIENTS meeting the following criteria:
- Hemoglobin less than 10.0 grams per deciliter.
- Active cardiac ischemia.
- Active significant bleed (decrease in hemoglobin of more than 2.0 grams per deciliter in 24 hours).
- Receipt of a blood transfusion during the current hospital admission.
Sites / Locations
- Yale New Haven Hospital Medical Intensive Care Unit (YNHH MICU) at St Raphael's Campus
- Yale New Haven Hospital Medical Intensive Care Unit (YNHH MICU) at York Street
Arms of the Study
Arm 1
Arm 2
Arm Type
No Intervention
Experimental
Arm Label
Control
Chronobundle
Arm Description
Usual ICU care.
The chronobundle will include bright daytime light, time-restricted intermittent feeding, enhanced exercise/mobility, and overnight sleep promotion.
Outcomes
Primary Outcome Measures
Circadian alignment change from normal
Individual urine 6-sulfatoxymelatonin acrophase compared to population normal acrophase of 03:30. Maximum difference +/- 12 hours.
Secondary Outcome Measures
Circadian alignment absolute time
Clock time of individual urine 6-sulfatoxymelatonin acrophase.
Change in Circadian alignment from day 1 to day 3
Change in individual urine 6-sulfatoxymelatonin acrophase between period 1 and period 3 (first 24 hours and last 24 hours of monitoring)
Circadian alignment based on diurnal heart rate variation
Individual heart rate nadir compared to population normal nadir of 04:00. Maximum difference +/- 12 hours.
Overnight sleep duration
Minutes of sleep from 22:00 to 05:59 as measured by NoxA1 portable polysomnography (PSG) device.
Overnight Rapid Eye Movement (REM) proportion
Proportion of Stage REM sleep from 22:00 to 05:59 as measured by NoxA1 portable polysomnography device.
Overnight non-rapid eye movement stage 3 (NREM3) proportion
Proportion of Stage NREM3 sleep from 22:00 to 05:59 as measured by NoxA1 portable polysomnography device.
Overnight arousal index (continuity)
Number of arousals per hour of sleep from 22:00 to 05:59 as measured by NoxA1 portable polysomnography device.
Daytime sleep duration
Minutes of sleep from 06:00 to 21:59 as measured by NoxA1 portable polysomnography device.
Daytime REM proportion
Proportion of Stage REM sleep from 06:00 to 21:59 as measured by NoxA1 portable polysomnography device.
Daytime NREM3 proportion
Proportion of Stage NREM3 sleep from 06:00 to 21:59 as measured by NoxA1 portable polysomnography device.
Daytime arousal index (continuity)
Number of arousals per hour of sleep from 06:00 to 21:59 as measured by NoxA1 portable polysomnography device.
Biologic night sleep duration
Minutes of sleep during biologic night (melatonin onset to offset) as measured by NoxA1 portable polysomnography device.
Biologic night REM proportion
Proportion of Stage REM sleep during biologic night (melatonin onset to offset) as measured by NoxA1 portable polysomnography device.
Biologic night NREM3 proportion
Proportion of Stage NREM3 sleep during biologic night (melatonin onset to offset) as measured by NoxA1 portable polysomnography device.
Biologic night arousal index (continuity)
Number of arousals per hour of sleep during biologic night (melatonin onset to offset)as measured by NoxA1 portable polysomnography device.
Atypical sleep
Presence of atypical sleep on polysomnography recording, characterized by δ waves without cyclic organization, the absence of K-complexes and sleep spindles, and unusual sleep stage transitions.
Glucose tolerance
Area under the curve per 24 hour period of continuous glucose monitoring.
Matsuda's Index
Matsuda Index to be calculated according to published algorithms from data produced during the oral glucose tolerance test.
Full Information
NCT ID
NCT05551325
First Posted
September 19, 2022
Last Updated
August 29, 2023
Sponsor
Yale University
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
1. Study Identification
Unique Protocol Identification Number
NCT05551325
Brief Title
Reestablishing Sleep and Circadian Alignment in MICU Patients Via a Mechanistic RCT of an Sleep Chronobundle
Acronym
ReAlign-ICU
Official Title
Reestablishing Sleep and Circadian Alignment in Medically Critically Ill Patients Via a Mechanistic Randomized Controlled Trial of an Intensive Care Unit (ICU) Sleep Chronobundle
Study Type
Interventional
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 2023 (Anticipated)
Primary Completion Date
June 2027 (Anticipated)
Study Completion Date
June 2028 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yale University
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
More than 5 million patients are admitted to the intensive care unit every year in the United States; most of these patients experience profound sleep and circadian disruption. Promotion of circadian alignment (i.e., alignment of the body's clocks) would make it possible to strategically schedule behaviors such as sleep and eating at normal body clock times, which is predicted to improve sleep quality and metabolic function. This project will test the ability of a sleep chronobundle (i.e., sleep promotion and circadian treatment bundle) to normalize circadian alignment and subsequently test if this realignment also improves sleep and metabolism.
Detailed Description
An evidence-based treatment that simultaneously addresses intensive care unit (ICU) sleep and circadian disruption (SCD) is desperately needed. Such treatment is needed because patients admitted to the ICU are at high risk for adverse outcomes resulting directly from acute SCD. It is well established among healthy controls that acute SCD is associated with immediate negative consequences such as metabolic, cognitive, cardiovascular, respiratory, skeletal muscle, and immune dysfunction. Normalization of sleep and circadian processes improves these dysfunctions. In the ICU, sleep and circadian processes cannot be segregated, and there are likely several overlapping domains of SCD (e.g., sleep duration, timing, architecture, and continuity, and circadian alignment and amplitude). Thus, a bundled approach to sleep and circadian promotion holds the most promise for reversing SCD, normalizing broader physiologic disruptions, and improving ICU outcomes.
To date, ICU sleep promotion bundles have had limited success in documenting improved sleep, and sleep bundles have commonly ignored circadian disruption and circadian-based sleep promotion strategies. This is a critical gap. Translation of circadian principles to ICU sleep promotion is essential because alignment between biologic and clock time allows for subsequent strategic scheduling of behaviors, for example, scheduling sleep promotion during the biologic night to improve sleep duration and quality. In addition, circadian alignment has broader physiologic implications and related potential to improve function across a wide variety of organ systems, for example, scheduling eating during the biologic day to improve glucose tolerance. Investigations to date have not tested the effect of a multifaceted intervention that includes promotion of both circadian alignment via photic and nonphotic zeitgebers and overnight sleep via non-pharmacologic strategies (sleep chronobundle).
The overall objective of this project is to test whether a sleep chronobundle, including daytime bright light, time-restricted daytime feeding, increased daytime mobility, and overnight sleep promotion mitigates ICU SCD. A mechanistic randomized controlled trial will be used to test our central hypotheses that a sleep chronobundle will (1) align biologic and clock day-night; (2) overlap behaviors (e.g., sleeping and eating) correctly with biologic time periods; and therefore (3) improve sleep and metabolic processes in the ICU. The focus of this study is on sleep and glucose metabolism metrics because of their high relevance to critical illness.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Critical Illness, Sleep Deprivation, Circadian Rhythm Sleep Disorder, Unspecified
Keywords
critical illness, sleep deficiency, circadian misalignment
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
1:1 randomization of patients to control or intervention
Masking
InvestigatorOutcomes Assessor
Masking Description
The investigator and statistical team will not know group assignment of patients enrolled in the study. Due to the nature of the intervention study staff, patients and care providers will be able to ascertain group assignment.
Allocation
Randomized
Enrollment
160 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Control
Arm Type
No Intervention
Arm Description
Usual ICU care.
Arm Title
Chronobundle
Arm Type
Experimental
Arm Description
The chronobundle will include bright daytime light, time-restricted intermittent feeding, enhanced exercise/mobility, and overnight sleep promotion.
Intervention Type
Other
Intervention Name(s)
Chronobundle - light
Intervention Description
Bright daytime light from 09:00 to 13:00 starting on day 1. The light will be 10,000 lux at 12" and provide a minimal intensity of 1,250 lux at the angle of the eye (30" to 36" distance). The light has a temperature of 5,000 Kelvin indicating a high blue wavelength content which should maximize circadian effects (validated device Sunbox Lighting, Maryland). Following the 09:00 to 13:00 bright light, the room lights will remain on and the curtains will remain open to maximize daytime light exposure while not decreasing bright light tolerance.
Intervention Type
Other
Intervention Name(s)
chronobundle - feeding
Intervention Description
Time restricted (daytime) intermittent feeding will include 4 meals delivered at 09:00, 12:00, 15:00 and 18:00. Each meal will include one-fourth of the recommended daily tube feed volume.
Intervention Type
Other
Intervention Name(s)
chronobundle - mobility
Intervention Description
Exercise/mobility sessions will occur twice per day between 09:00 and 16:00; intensity will be determined by clinical status and documented in the chart by our physical therapy service.
Intervention Type
Other
Intervention Name(s)
chronobundle - sleep
Intervention Description
Overnight sleep promotion will occur between 22:00 and 06:00 with a more restricted sleep period between 00:00 and 04:00. This will be achieved by rescheduling non-urgent care. There will be no changes to urgent care. Additionally, room lights will be dimmed, curtains drawn, and room doors closed. Television screens will be fitted with blue light-blocking filters.
Primary Outcome Measure Information:
Title
Circadian alignment change from normal
Description
Individual urine 6-sulfatoxymelatonin acrophase compared to population normal acrophase of 03:30. Maximum difference +/- 12 hours.
Time Frame
post-treatment, 72 hours
Secondary Outcome Measure Information:
Title
Circadian alignment absolute time
Description
Clock time of individual urine 6-sulfatoxymelatonin acrophase.
Time Frame
post-treatment, 72 hours
Title
Change in Circadian alignment from day 1 to day 3
Description
Change in individual urine 6-sulfatoxymelatonin acrophase between period 1 and period 3 (first 24 hours and last 24 hours of monitoring)
Time Frame
Day 1 and post-treatment, 72 hours
Title
Circadian alignment based on diurnal heart rate variation
Description
Individual heart rate nadir compared to population normal nadir of 04:00. Maximum difference +/- 12 hours.
Time Frame
post-treatment, 72 hours
Title
Overnight sleep duration
Description
Minutes of sleep from 22:00 to 05:59 as measured by NoxA1 portable polysomnography (PSG) device.
Time Frame
post-treatment, 72 hours
Title
Overnight Rapid Eye Movement (REM) proportion
Description
Proportion of Stage REM sleep from 22:00 to 05:59 as measured by NoxA1 portable polysomnography device.
Time Frame
post-treatment, 72 hours
Title
Overnight non-rapid eye movement stage 3 (NREM3) proportion
Description
Proportion of Stage NREM3 sleep from 22:00 to 05:59 as measured by NoxA1 portable polysomnography device.
Time Frame
post-treatment, 72 hours
Title
Overnight arousal index (continuity)
Description
Number of arousals per hour of sleep from 22:00 to 05:59 as measured by NoxA1 portable polysomnography device.
Time Frame
post-treatment, 72 hours
Title
Daytime sleep duration
Description
Minutes of sleep from 06:00 to 21:59 as measured by NoxA1 portable polysomnography device.
Time Frame
post-treatment, 72 hours
Title
Daytime REM proportion
Description
Proportion of Stage REM sleep from 06:00 to 21:59 as measured by NoxA1 portable polysomnography device.
Time Frame
post-treatment, 72 hours
Title
Daytime NREM3 proportion
Description
Proportion of Stage NREM3 sleep from 06:00 to 21:59 as measured by NoxA1 portable polysomnography device.
Time Frame
post-treatment, 72 hours
Title
Daytime arousal index (continuity)
Description
Number of arousals per hour of sleep from 06:00 to 21:59 as measured by NoxA1 portable polysomnography device.
Time Frame
post-treatment, 72 hours
Title
Biologic night sleep duration
Description
Minutes of sleep during biologic night (melatonin onset to offset) as measured by NoxA1 portable polysomnography device.
Time Frame
post-treatment, 72 hours
Title
Biologic night REM proportion
Description
Proportion of Stage REM sleep during biologic night (melatonin onset to offset) as measured by NoxA1 portable polysomnography device.
Time Frame
post-treatment, 72 hours
Title
Biologic night NREM3 proportion
Description
Proportion of Stage NREM3 sleep during biologic night (melatonin onset to offset) as measured by NoxA1 portable polysomnography device.
Time Frame
post-treatment, 72 hours
Title
Biologic night arousal index (continuity)
Description
Number of arousals per hour of sleep during biologic night (melatonin onset to offset)as measured by NoxA1 portable polysomnography device.
Time Frame
post-treatment, 72 hours
Title
Atypical sleep
Description
Presence of atypical sleep on polysomnography recording, characterized by δ waves without cyclic organization, the absence of K-complexes and sleep spindles, and unusual sleep stage transitions.
Time Frame
post-treatment, 72 hours
Title
Glucose tolerance
Description
Area under the curve per 24 hour period of continuous glucose monitoring.
Time Frame
post-treatment, 72 hours
Title
Matsuda's Index
Description
Matsuda Index to be calculated according to published algorithms from data produced during the oral glucose tolerance test.
Time Frame
post-treatment, 72 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion:
MICU patients admitted within 24 hours as of 09:00 on day of enrollment (study day 1).
Intubated and not having passed a spontaneous breathing trial or expected to be extubated in the next 24 hours as of enrollment.
Age greater than or equal to 18 years old.
Exclusion:
Not expected to make >250 mL urine per 24 hours.
Imminently dying or with a hospice status.
At significant risk for pre-existing circadian abnormalities including: (1) severe chronic brain injury (injury greater than 30 days ago resulting in the inability to live independently); (2) acute brain injury of any severity (injury less than 30 days ago including acute intracranial bleed, traumatic brain injury, central nervous system infection, tumor); (3) documented circadian disorder (<1% population) or blind/disease of the optic nerve; (4) current or recent (last 1 year) shiftwork; and (5) homelessness, incarceration, or institutionalization.
At elevated risk of aspiration due to structural or functional abnormality of the gastrointestinal tract.
Admitted to the ICU for treatment of diabetic ketoacidosis or hyperosmolar state; this diagnosis will be established via review of the medical record for a description of diabetes in the past medical history or the presence of diabetes medication on the confirmed home medication list AND hyperglycemia attributed to diabetic ketoacidosis or diabetic hyperosmolar state by the admitting care team in their written assessment of the patient.
Having a history of hypoglycemia without documented full neurological recovery; this diagnosis will be established via review of the patient's past medical history in the medical record;
Having a history suggesting an abnormally high risk of suffering hypoglycemia (e.g., known insulin secreting tumor, history of unexplained or recurrent hypoglycemia or fulminant hepatic failure); this diagnosis will be established via review of the patient's past medical history in the medical record.
Admitted due to complications of a suicide attempt.
Admitted due to an acute drug overdose or active alcohol withdrawal.
For the Oral glucose tolerance testing sub-study, we will EXCLUDE PATIENTS meeting the following criteria:
Hemoglobin less than 10.0 grams per deciliter.
Active cardiac ischemia.
Active significant bleed (decrease in hemoglobin of more than 2.0 grams per deciliter in 24 hours).
Receipt of a blood transfusion during the current hospital admission.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Melissa P Knauert, MD, PhD
Phone
203-785-4163
Email
melissa.knauert@yale.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Melissa P Knauert, MD, PhD
Organizational Affiliation
Yale University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Yale New Haven Hospital Medical Intensive Care Unit (YNHH MICU) at St Raphael's Campus
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06520
Country
United States
Facility Name
Yale New Haven Hospital Medical Intensive Care Unit (YNHH MICU) at York Street
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06520
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Reestablishing Sleep and Circadian Alignment in MICU Patients Via a Mechanistic RCT of an Sleep Chronobundle
We'll reach out to this number within 24 hrs